Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Insight into Glial Biology and Diseases.

Neuroscience bulletin·2023
Same author

Highly efficient Förster resonance energy transfer between an emissive tetraphenylethylene-based metal-organic cage and the encapsulated dye guest.

Chemical science·2023
Same author

Ideal acoustic quantum spin Hall phase in a multi-topology platform.

Nature communications·2023
Same author

Prognosis for intrahepatic cholangiocarcinoma after liver transplantation by size of tumor.

Surgery·2023
Same author

Induction of transmucosal protection by oral vaccination with an attenuated <i>Chlamydia</i>.

bioRxiv : the preprint server for biology·2023
Same author

Prediction of Compressive Strength of Fly Ash-Slag Based Geopolymer Paste Based on Multi-Optimized Artificial Neural Network.

Materials (Basel, Switzerland)·2023

Related Experiment Video

Updated: Jul 9, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Integrated Genomic, Transcriptomic, and Circulating Biomarkers Predict Benefit to Immune Checkpoint Inhibitor Plus

Lailing Li1,2, Dandan Han3,4, Xiaoliang Zhang5,6

  • 1Department of Respiratory Oncology The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei China.

Medcomm
|July 8, 2026
PubMed
Summary

Biomarkers from tumor DNA, RNA, and ctDNA can predict treatment success in advanced non-small cell lung cancer (NSCLC) patients receiving immunotherapy plus chemotherapy. Identifying these markers helps optimize treatment strategies for better outcomes.

Keywords:
circulating tumor DNAcombination immunotherapyimmune checkpoint inhibitorsmulti‐omicsnon‐small cell lung cancerpredictive biomarkers

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Jul 9, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Area of Science:

  • Oncology
  • Genomics
  • Immunotherapy

Background:

  • Combined immune checkpoint inhibitor (ICI) and chemotherapy is standard for advanced non-small cell lung cancer (NSCLC).
  • Reliable biomarkers predicting clinical benefit are currently lacking.
  • Personalized treatment strategies are needed to improve patient outcomes.

Purpose of the Study:

  • To identify predictive biomarkers for advanced NSCLC patients treated with first-line ICI plus chemotherapy.
  • To assess the association between genomic, transcriptomic, and circulating tumor DNA (ctDNA) features and treatment response.
  • To explore the potential of multi-omics data for optimizing immunotherapy.

Main Methods:

  • Analysis of 54 advanced NSCLC patients receiving first-line ICI plus chemotherapy.
  • Targeted DNA and RNA sequencing of pretreatment tumor biopsies.
  • Longitudinal ctDNA profiling from plasma samples.
  • Assessment of associations between molecular features and objective response rate (ORR) and progression-free survival (PFS).

Main Results:

  • LRP1B mutations predicted longer PFS, while FBXW7 mutations predicted shorter PFS.
  • High SPP1 and LHCGR expression indicated poor prognosis; high IL24 expression correlated with longer PFS.
  • Higher CD8+ effector memory T-cell infiltration was observed in responders.
  • Longitudinal ctDNA positivity at multiple timepoints was associated with inferior PFS.

Conclusions:

  • Multi-omics analysis integrating genomic, transcriptomic, and ctDNA data can identify predictive biomarkers for NSCLC.
  • These biomarkers have the potential to optimize immunotherapy strategies.
  • Further validation is needed to implement these findings in clinical practice.